Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Sintalica Bioscience, a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, reviewed approval for the synthesis and detention of Schedule I drugs including psilocybin, psilocin and other derived tryptamines.
Additionally, it has received approval for the cultivation of psilocybe mushrooms and extraction of tryptamines and along with a positive opinion for the initiation of safety and efficacy testing.
This combination of authorisations is unique in Europe and will allow Sintalica to pursue its full research and development and clinical programme at the University’s laboratory and related facilities.
Chairman and Co-Founder of Sintalica, Bruce Linton, commented: “These authorisations are critical to Sintalica’s ongoing drug discovery programme.
“We are confident our non-hallucinogenic psychedelic molecules can lead to breakthrough treatments for neuroinflammatory diseases affecting millions of patients worldwide.”
Th company has stated that its approach to psychedelic drug discovery focuses on minimising hallucinogenic effects while enhancing the psychedelic molecule’s strong anti-inflammatory properties.
Sintalica’s research and drug development programme is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation.
The company has so far filed three provisional patents for proprietary psychedelic molecules with claims of improved stability, efficacy and bioavailability. The molecules are being produced in the University’s state-of-the-art laboratories, and will be tested for safety and efficacy toward target indications.
Sintalica also has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccolò Cusano of Rome.
Rector of the University of Messina, Professor Salvatore Cuzzocrea, commented: “Today, we mark the final development phase for this important project.
“It is the culmination of more than one year of teamwork and planning by Sintalica and the University of Messina, in collaboration with Niccolò Cusano University of Rome, that will result in more efficient and more productive organic and biotech synthesis, cultivation, delivery and in vivo trials of psychedelic drugs under one roof.”
